- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07815353
ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among COPD Patients (ECHO-COPD)
Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Cost Among COPD Patients at Buraidah Central Hospital in Al-Qassim Region, Saudi Arabia: A Quasi-Experimental Design
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia.
A quantitative, quasi-experimental pretest-posttest control-group design will be used. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will continue to receive standard care without additional educational input. Baseline assessments will include medication adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
The HBM will guide the content and delivery of the pharmacist-led educational intervention. The intervention will address the six core constructs of the HBM:
- Perceived susceptibility
- Perceived severity
- Perceived benefits
- Perceived barriers
- Cues to action
- Self-efficacy The purpose of applying the HBM is to influence patients' understanding of COPD and promote positive behavioural changes, particularly improvements in medication adherence. The study will then examine the relationship between these improvements and quality of life, healthcare utilisation, and direct healthcare costs.
The intervention will consist of structured face-to-face educational sessions conducted in the designated counselling room of the Pulmonary Department at BCH. Sessions will incorporate printed educational materials, lectures, counselling, practical demonstrations, motivational support, problem-solving strategies, and reinforcement of behavioural changes.
The educational programme will cover aspects of COPD management, medication adherence and appropriate medication use, COPD risk factors and complications, nutrition and preventive care, smoking cessation, barriers to recommended behaviours, cues to action, and strategies to improve patients' confidence in managing COPD.
Participants in the intervention and control groups will undergo pre-intervention assessments. Participants in the intervention group will subsequently receive the structured educational programme, while the control group will continue to receive standard care without additional educational input. Post-intervention assessments will use the same measurement instruments to allow within-group and between-group comparisons.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Bander S Alshammeri, MSc
- Puhelinnumero: +966509466669
- Sähköposti: bandershe3@gmail.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Rabia Hussain, PhD, Lecturer
- Puhelinnumero: +6046534085
- Sähköposti: rabia.hussain@usm.my
Opiskelupaikat
-
-
Al-Qassim Region
-
Buraidah, Al-Qassim Region, Saudi-Arabia, 52391
- Bander S Alshammeri
-
Ottaa yhteyttä:
- Bander S Alshammeri, MSc
- Puhelinnumero: +966509466669
- Sähköposti: bandershe3@gmail.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
Participants must:
- Be adults aged 18-65 years.
- Be diagnosed with COPD stages I-III according to GOLD guidelines.
- Have visited or been admitted for a COPD exacerbation and be receiving care at BCH in Al-Qassim Region, Saudi Arabia.
- Be Arabic-speaking and capable of understanding study instructions.
- Be willing and able to provide written informed consent.
Exclusion Criteria:
Participants will be excluded if they:
- Are diagnosed with COPD stage IV.
Have another significant pulmonary disease, including:
- Asthma
- Bronchiectasis
- Pneumonia
- Cystic fibrosis
Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including:
- Hepatic dysfunction
- Renal dysfunction
- Psychiatric impairment
- Sensory impairment
- Are immunocompromised or receiving immunosuppressive treatment.
- Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: HBM-Based Educational Intervention
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM. The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department. The programme will be delivered from study months 4 to 9. Educational sessions will include:
|
|
Ei väliintuloa: Standard Care
Participants in the control group will continue to receive routine/standard care provided by BCH. They will not receive the additional structured pharmacist-led HBM-based educational intervention. Both intervention and control participants will undergo the same baseline and post-intervention assessments. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Medication Adherence
Aikaikkuna: Baseline and 6 months after initiation of the educational intervention.
|
Change in medication adherence Measurement Tool 8-item Morisky Medication Adherence Scale (MMAS-8), prevalidated Arabic version Medication adherence will be assessed using MMAS-8 at baseline and following completion of the intervention.
|
Baseline and 6 months after initiation of the educational intervention.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Quality of Life and Health Status
Aikaikkuna: Baseline and 6 months after initiation of the educational intervention.
|
Change in quality of life/health status Measurement Tool COPD Assessment Test (CAT), prevalidated Arabic version The CAT will be administered to participants in both groups at baseline and after completion of the intervention.
|
Baseline and 6 months after initiation of the educational intervention.
|
|
Direct Healthcare Costs
Aikaikkuna: Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
Change in direct medical costs associated with COPD Direct medical cost data will be obtained from the clinical cost centre of BCH. The costing analysis will include direct COPD-related healthcare resources such as:
Important Costing Specification The cost of delivering the educational intervention will not be included in the costing analysis. The economic component of this study focuses on the direct cost of illness associated with COPD rather than the cost of implementing the educational intervention. |
Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
HBM Constructs
Aikaikkuna: Baseline and 6 months after initiation of the educational intervention.
|
Changes in patients' health beliefs will be assessed using a structured, prevalidated Arabic HBM questionnaire. The questionnaire assesses:
|
Baseline and 6 months after initiation of the educational intervention.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Krooninen sairaus
- Sairauden ominaisuudet
- Hengityselinten sairaudet
- Keuhkosairaudet
- Keuhkosairaudet, obstruktiiviset
- Patologiset tilat, merkit ja oireet
- Käyttäytyminen
- Hoidon noudattaminen ja noudattaminen
- Terveyskäyttäytyminen
- Potilaan noudattaminen
- Potilaiden terveydenhuollon hyväksyminen
- Keuhkosairaus, krooninen obstruktiivinen
- Lääkkeen noudattaminen
Muut tutkimustunnusnumerot
- USM-DSAP-2026-002
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .